These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 32878700)

  • 1. Short-term impact of co-payment level increase on the use of medication and patient-reported outcomes in Finnish patients with type 2 diabetes.
    Lavikainen P; Aarnio E; Niskanen L; Mäntyselkä P; Martikainen J
    Health Policy; 2020 Dec; 124(12):1310-1316. PubMed ID: 32878700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of co-payment level increase of antidiabetic medications on glycaemic control: an interrupted time-series study among Finnish patients with type 2 diabetes.
    Lavikainen P; Aarnio E; Jalkanen K; Tirkkonen H; Rautiainen P; Laatikainen T; Martikainen J
    BMC Health Serv Res; 2020 Nov; 20(1):1095. PubMed ID: 33246453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of use of diabetic medication and clinical guidelines in four Nordic countries.
    Järvinen S; Laine MK; Eriksson JG
    Ann Med; 2016; 48(3):162-8. PubMed ID: 26890317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of reimbursement reform of antidiabetic medicines from the patients' perspective - a survey among patients with type 2 diabetes in Finland.
    Suviranta T; Timonen J; Martikainen J; Aarnio E
    BMC Health Serv Res; 2019 Oct; 19(1):769. PubMed ID: 31665003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
    Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
    Am J Manag Care; 2019 May; 25(5):231-238. PubMed ID: 31120717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program.
    Walker EA; Molitch M; Kramer MK; Kahn S; Ma Y; Edelstein S; Smith K; Johnson MK; Kitabchi A; Crandall J
    Diabetes Care; 2006 Sep; 29(9):1997-2002. PubMed ID: 16936143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
    JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The present and future treatment of pediatric type 2 diabetes.
    Van Name MA; Guandalini C; Steffen A; Patel A; Tamborlane W
    Expert Rev Endocrinol Metab; 2018 Jul; 13(4):207-212. PubMed ID: 30063424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
    Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register.
    Maple-Brown LJ; Lindenmayer G; Barzi F; Whitbread C; Connors C; Moore E; Boyle J; Kirkwood M; Lee IL; Longmore D; van Dokkum P; Wicks M; Dowden M; Inglis C; Cotter M; Kirkham R; Corpus S; Chitturi S; Thomas S; O'Dea K; Zimmet P; Oats J; McIntyre HD; Brown A; Shaw JE;
    J Diabetes; 2019 Sep; 11(9):761-770. PubMed ID: 30680949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
    Hosio M; Urpilainen E; Marttila M; Hautakoski A; Arffman M; Sund R; Puistola U; Läärä E; Jukkola A; Karihtala P
    Breast Cancer Res Treat; 2019 Jun; 175(3):741-748. PubMed ID: 30895533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
    Guardado-Mendoza R; Salazar-López SS; Álvarez-Canales M; Farfán-Vázquez D; Martínez-López YE; Jiménez-Ceja LM; Suárez-Pérez EL; Angulo-Romero F; Evia-Viscarra ML; Montes de Oca-Loyola ML; Durán-Pérez EG; Folli F; Aguilar-García A
    Metabolism; 2020 Mar; 104():154054. PubMed ID: 31887309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization.
    Genovese S; Tedeschi D
    Adv Ther; 2013 Feb; 30(2):152-64. PubMed ID: 23430354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
    Noh Y; Jeon SM; Shin S
    Int J Cancer; 2019 Apr; 144(7):1530-1539. PubMed ID: 30229901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP).
    Duru OK; Turk N; Ettner SL; Neugebauer R; Moin T; Li J; Kimbro L; Chan C; Luchs RH; Keckhafer AM; Kirvan A; Ho S; Mangione CM
    J Gen Intern Med; 2015 Nov; 30(11):1645-50. PubMed ID: 25944019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.